文献速递前列腺癌

HOXB13 G84E突变与前列腺癌风险

Homeobox B13 G84E Mutation and Prostate Cancer Risk.
PubMed 文献 · Eur Urol · 2018-12-08

该研究结合系统综述与meta分析及一项针对11983例前列腺癌患者的kin-cohort研究,评估HOXB13 G84E突变携带者的前列腺癌风险。meta分析显示未选择家族史的病例对照研究中合并相对风险为3.43(95%CI 2.78-4.23);kin-cohort研究中携带者风险随家族史和出生队列变化,85岁时绝对风险从60%至98%不等,而非携带者为15%。结论强调咨询应基于个体化的年龄别绝对风险而非平均风险。

要点

  • HOXB13 G84E携带者的前列腺癌风险异质,应结合家族史和出生队列个体化评估。
  • 未选择家族史的病例对照研究合并相对风险为3.43(95%CI 2.78-4.23)。
  • 携带者85岁时绝对风险从60%(无家族史)至98%(两名年轻亲属患病)不等。

核心结论

  • HOXB13 G84E突变携带者的前列腺癌风险异质,咨询应基于个体化的年龄别绝对风险而非平均风险。

研究设计与样本

  • 系统综述与meta分析已发表的相对风险估计。
  • kin-cohort研究纳入1993-2014年英国189家医院的11983例前列腺癌患者,均检测HOXB13 G84E。
  • 采用复杂分离分析并进行确认调整,推导适用于人群的年龄别风险。

主要发现

  • 病例对照研究间相对风险存在显著异质性(范围0.95-33.0,p<0.001),且因病例选择而异(p=0.007)。
  • 未选择前列腺癌家族史的病例对照研究合并相对风险为3.43(95%CI 2.78-4.23)。
  • kin-cohort研究中携带者风险随家族史变化(p<0.001)。
  • 相对风险随年龄降低的趋势不显著(p=0.068);出生队列较晚者相对风险更高(p=0.004):1929年及以前出生者为3.09(95%CI 2.03-4.71),1930年及以后出生者为5.96(95%CI 4.01-8.88)。
  • 85岁时携带者绝对风险从无家族史的60%至两名年轻亲属患病的98%,非携带者平均为15%。

关键数值与推荐

  • 未选择家族史的病例对照研究合并相对风险:3.43(95%CI 2.78-4.23)。
  • 1929年及以前出生者相对风险:3.09(95%CI 2.03-4.71);1930年及以后出生者:5.96(95%CI 4.01-8.88)。
  • 85岁时绝对风险:无家族史携带者60%,两名年轻亲属患病携带者98%,非携带者平均15%。

临床怎么用

  • 对HOXB13 G84E携带者进行遗传咨询时,应结合家族史和出生队列评估年龄别绝对风险,而非使用平均风险。
  • 可根据个体化风险调整前列腺癌筛查频率等风险管理选项。

局限性

  • 依赖自我报告的癌症家族史。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The homeobox B13 (HOXB13) G84E mutation has been recommended for use in genetic counselling for prostate cancer (PCa), but the magnitude of PCa risk conferred by this mutation is uncertain. OBJECTIVE: To obtain precise risk estimates for mutation carriers and information on how these vary by family history and other factors. DESIGN, SETTING, AND PARTICIPANTS: Two-fold: a systematic review and meta-analysis of published risk estimates, and a kin-cohort study comprising pedigree data on 11983 PCa patients enrolled during 1993-2014 from 189 UK hospitals and who had been genotyped for HOXB13 G84E. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Relative and absolute PCa risks. Complex segregation analysis with ascertainment adjustment to derive age-specific risks applicable to the population, and to investigate how these vary by family history and birth cohort. RESULTS AND LIMITATIONS: A meta-analysis of case-control studies revealed significant heterogeneity between reported relative risks (RRs; range: 0.95-33.0, p<0.001) and differences by case selection (p=0.007). Based on case-control studies unselected for PCa family history, the pooled RR estimate was 3.43 (95% confidence interval [CI] 2.78-4.23). In the kin-cohort study, PCa risk for mutation carriers varied by family history (p<0.001). There was a suggestion that RRs decrease with age, but this was not significant (p=0.068). We found higher RR estimates for men from more recent birth cohorts (p=0.004): 3.09 (95% CI 2.03-4.71) for men born in 1929 or earlier and 5.96 (95% CI 4.01-8.88) for men born in 1930 or later. The absolute PCa risk by age 85 for a male HOXB13 G84E carrier varied from 60% for those with no PCa family history to 98% for those with two relatives diagnosed at young ages, compared with an average risk of 15% for noncarriers. Limitations include the reliance on self-reported cancer family history. CONCLUSIONS: PCa risks for HOXB13 G84E mutation carriers are heterogeneous. Counselling should not be based on average risk estimates but on age-specific absolute risk estimates tailored to individual mutation carriers' family history and birth cohort. PATIENT SUMMARY: Men who carry a hereditary mutation in the homeobox B13 (HOXB13) gene have a higher than average risk for developing prostate cancer. In our study, we examined a large number of families of men with prostate cancer recruited across UK hospitals, to assess what other factors may contribute to this risk and to assess whether we could create a precise model to help in predicting a man's prostate cancer risk. We found that the risk of developing prostate cancer in men who carry this genetic mutation is also affected by a family history of prostate cancer and their year of birth. This information can be used to assess more personalised prostate cancer risks to men who carry HOXB13 mutations and hence better counsel them on more personalised risk management options, such as tailoring prostate cancer screening frequency.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Nyberg T, Govindasami K, Leslie G, et al. Homeobox B13 G84E Mutation and Prostate Cancer Risk. Eur Urol. 2018. PMID: 30527799. doi:10.1016/j.eururo.2018.11.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。